72 related articles for article (PubMed ID: 25397538)
21. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
[TBL] [Abstract][Full Text] [Related]
22. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
24. Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens.
Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Vergani B; Morosi M; Colella E; Galli M; Rusconi S
J Int AIDS Soc; 2014; 17(4 Suppl 3):19830. PubMed ID: 25397574
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients.
Bernardino JI; Zamora FX; Valencia E; Moreno V; Vergas J; Tellez MJ; Estrada V; Gonzalez-Garcia J
J Int AIDS Soc; 2014; 17(4 Suppl 3):19787. PubMed ID: 25397531
[TBL] [Abstract][Full Text] [Related]
26. Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.
Stellbrink HJ; Antinori A; Pozniak A; Flamm J; Bredeek F; Patel K; Garner W; Piontkowsky D
J Int AIDS Soc; 2014; 17(4 Suppl 3):19793. PubMed ID: 25397537
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
28. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
29. Hypovitaminosis D in HIV-infected patients in Lisbon: a link with antiretroviral treatment.
Boura M; Sutre AF; Badura R; Zagalo A; Afonso C; Caldeira L; Valadas E
J Int AIDS Soc; 2014; 17(4 Suppl 3):19826. PubMed ID: 25397570
[TBL] [Abstract][Full Text] [Related]
30. Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.
Borghetti A; Mondi A; Piccoli B; Gagliardini R; Lamonica S; Ciccarelli N; D'Avino A; Pallavicini F; Cauda R; De Luca A; Fabbiani M; Di Giambenedetto S
J Int AIDS Soc; 2014; 17(4 Suppl 3):19817. PubMed ID: 25397561
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial.
Petchkum P; Sungkanuparph S; Kiertiburanakul S; Phuphuakrat A
Open Forum Infect Dis; 2019 Apr; 6(4):ofz155. PubMed ID: 31041351
[TBL] [Abstract][Full Text] [Related]
34. Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients.
Casado JL; Bañón S; Moreno A; de Santiago AD; Gomez C; Perez-Elías MJ; Moreno S
J Int AIDS Soc; 2014; 17(4 Suppl 3):19801. PubMed ID: 25397545
[TBL] [Abstract][Full Text] [Related]
35. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
Kiertiburanakul S; Malathum K; Watcharananan S; Sathapatayavongs B; Sungkanuparph S
Int J STD AIDS; 2009 Mar; 20(3):176-9. PubMed ID: 19255265
[TBL] [Abstract][Full Text] [Related]
36. [Nevirapine related hepatotoxicity: the prevalence and risk factors in a cohort of ART naive Han Chinese with AIDS].
Gao SC; Gui XE; Deng LP; Zhang YX; Yan YJ; Rong YP; Liang K; Yang RR
Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):689-93. PubMed ID: 20943082
[TBL] [Abstract][Full Text] [Related]
37. The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART.
Kiselinova M; Anna M; Malatinkova E; Vervish K; Beloukas A; Messiaen P; Bonczkowski P; Trypsteen W; Callens S; Verhofstede C; De Spiegelaere W; Vandekerckhove L
J Int AIDS Soc; 2014; 17(4 Suppl 3):19823. PubMed ID: 25397567
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Gathe J; Andrade-Villanueva J; Santiago S; Horban A; Nelson M; Cahn P; Bogner J; Spencer D; Podzamczer D; Yong CL; Nguyen T; Zhang W; Drulak M; Quinson AM
Antivir Ther; 2011; 16(5):759-69. PubMed ID: 21817198
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
